These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23374099)

  • 1. Practical and cost-effective measurement of B-domain deleted and full-length recombinant FVIII in the routine haemostasis laboratory.
    Cauchie M; Toelen J; Peerlinck K; Jacquemin M
    Haemophilia; 2013 May; 19(3):e133-8. PubMed ID: 23374099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII.
    Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TA; Walker ID
    Haemophilia; 2016 Sep; 22(5):806-12. PubMed ID: 27217329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards.
    Morfini M; Cinotti S; Bellatreccia A; Paladino E; Gringeri A; Mannucci PM;
    J Thromb Haemost; 2003 Nov; 1(11):2283-9. PubMed ID: 14629459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of the new ReFacto AF Laboratory Standard allows reliable measurement of FVIII:C levels in ReFacto AF mock plasma samples by a one-stage clotting assay.
    Pouplard C; Caron C; Aillaud MF; Ternisien C; Desconclois C; Dubanchet A; Sobas F
    Haemophilia; 2011 Sep; 17(5):e958-62. PubMed ID: 21457408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII).
    Santoro C; Iorio A; Ferrante F; Pallotta A; Pignoloni P; Biondo F; Agnelli G; Mazzucconi MG
    Haemophilia; 2009 May; 15(3):779-87. PubMed ID: 19298379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays.
    Ingerslev J; Jankowski MA; Weston SB; Charles LA;
    J Thromb Haemost; 2004 Apr; 2(4):623-8. PubMed ID: 15102018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of B-domain-deleted ReFacto AF activity with a product-specific standard is affected by choice of reagent and patient-specific factors.
    Jacquemin M; Vodolazkaia A; Toelen J; Schoeters J; Van Horenbeeck I; Vanlinthout I; Debasse M; Peerlinck K
    Haemophilia; 2018 Jul; 24(4):675-682. PubMed ID: 28124445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A blinded in vitro study with Refacto mock plasma samples: similar FVIII results between the chromogenic assay and a one-stage assay when using a higher cephalin dilution.
    Caron C; Dautzenberg MD; Delahousse B; Droulle C; Pouzol P; Dubanchet A; Rothschild C
    Haemophilia; 2002 Sep; 8(5):639-43. PubMed ID: 12199672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Factor VIII assays in treated hemophilia A patients].
    Lasne D; Pouplard C; Nougier C; Eschwege V; Le Cam Duchez V; Proulle V; Smahi M; Harzallah I; Voisin S; Toulon P; Sobas F; Galinat H; Flaujac C; Ternisien C; Jeanpierre E;
    Ann Biol Clin (Paris); 2019 Feb; 77(1):53-65. PubMed ID: 30799298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BAY 81-8973, a full-length recombinant factor VIII: results from an International comparative laboratory field study.
    Kitchen S; Beckmann H; Katterle Y; Bruns S; Tseneklidou-Stoeter D; Maas Enriquez M
    Haemophilia; 2016 May; 22(3):e192-9. PubMed ID: 27030173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE.
    Turecek PL; Romeder-Finger S; Apostol C; Bauer A; Crocker-Buqué A; Burger DA; Schall R; Gritsch H
    Haemophilia; 2016 Nov; 22(6):957-965. PubMed ID: 27353010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators.
    Dodt J; Hubbard AR; Wicks SJ; Gray E; Neugebauer B; Charton E; Silvester G
    Haemophilia; 2015 Jul; 21(4):543-9. PubMed ID: 25623631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations.
    Barrowcliffe TW; Raut S; Sands D; Hubbard AR
    Semin Thromb Hemost; 2002 Jun; 28(3):247-56. PubMed ID: 12098084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories.
    St Ledger K; Feussner A; Kalina U; Horn C; Metzner HJ; Bensen-Kennedy D; Blackman N; Veldman A; Stowers A; Friedman KD
    J Thromb Haemost; 2018 Mar; 16(3):555-564. PubMed ID: 29274194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
    Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
    Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potency estimation of recombinant factor VIII: effect of assay method and standard.
    Hubbard AR; Bevan SA; Weller LJ
    Br J Haematol; 2001 May; 113(2):533-6. PubMed ID: 11380427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accurate measurement of extended half-life and unmodified factor VIII low levels with one-stage FVIII assays is dependent on the matrix of calibration curves.
    Van den Bossche D; Toelen J; Schoeters J; Van Horenbeeck I; Vanlinthout I; Debasse M; Peerlinck K; Jacquemin M
    Haemophilia; 2019 Jan; 25(1):e19-e26. PubMed ID: 30589148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A.
    Di Paola J; Smith MP; Klamroth R; Mannucci PM; Kollmer C; Feingold J; Kessler C; Pollmann H; Morfini M; Udata C; Rothschild C; Hermans C; Janco R
    Haemophilia; 2007 Mar; 13(2):124-30. PubMed ID: 17286764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromogenic assay for BAY 81-8973 potency assignment has no impact on clinical outcome or monitoring in patient samples.
    Kitchen S; Katterle Y; Beckmann H; Maas Enriquez M
    J Thromb Haemost; 2016 Jun; 14(6):1192-9. PubMed ID: 27002680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant to modified factor VIII and factor IX - chromogenic and one-stage assays issues.
    Kitchen S; Kershaw G; Tiefenbacher S
    Haemophilia; 2016 Jul; 22 Suppl 5():72-7. PubMed ID: 27405680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.